Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
PLoS Negl Trop Dis ; 5(12): e1412, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-22247786

RESUMEN

New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases. Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated dataset of 744 hits. We discuss the prioritization of these hits for each pathogen and the strong correlation observed between compounds active against more than two pathogens and mammalian cell toxicity. Our work suggests that the efficiency of early drug discovery for neglected diseases can be enhanced through a collaborative, multi-pathogen approach.


Asunto(s)
Antiparasitarios/aislamiento & purificación , Evaluación Preclínica de Medicamentos/métodos , Enfermedades Desatendidas/tratamiento farmacológico , Enfermedades Parasitarias/tratamiento farmacológico , Descubrimiento de Drogas/tendencias , Humanos
2.
J Biomol Screen ; 11(8): 996-1004, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17092920

RESUMEN

Protein tyrosine phosphatases (PTPs) play key roles in regulating tyrosine phosphorylation levels in cells. Since the discovery of PTP1B as a major drug target for diabetes and obesity, PTPs have emerged as a new and promising class of signaling targets for drug development in a variety of therapeutic areas. The routine use of generic substrate 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in our hands led to the discovery of very similar and often not very selective molecules. Therefore, to increase the chances to discover novel chemical scaffolds, a side-by-side comparison between the DiFMUP assay and a chip-based mobility shift assay with a specific phosphopeptide was performed, on 1 PTP, using a focused set of compounds. Assay robustness and sensitivity were comparable for both the DiFMUP and mobility shift assays. The off-chip mobility shift assay required a longer development time because of identification, synthesis, and characterization of a specific peptide, and its cost per point was higher. However, although most potent scaffolds found with the DiFMUP assay were confirmed in the mobility shift format, the off-chip mobility shift assay led to the identification of previously unidentified chemical scaffolds with improved druglike properties.


Asunto(s)
Ensayo de Cambio de Movilidad Electroforética/métodos , Microfluídica/métodos , Proteínas Tirosina Fosfatasas/antagonistas & inhibidores , Evaluación Preclínica de Medicamentos/métodos , Peptidil Transferasas , Relación Estructura-Actividad , Vanadatos/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA